On October 11, 2024, Adam Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (MLYS, Financial), sold 10,757 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 236,854 shares of Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and cardiorenal diseases. The company aims to address the unmet medical needs in these areas with precision medicine.
The shares were sold at a price of $13.57 each, valuing the transaction at approximately $145,982.49. This sale is part of a broader trend observed over the past year, where the insider has sold a total of 118,329 shares and made no purchases. The recent activities contribute to an overall pattern of 10 insider sells and 2 insider buys within the company over the last year.
The stock of Mineralys Therapeutics Inc currently holds a market cap of approximately $681.255 million. The price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are key metrics that potential investors might consider in evaluating the company's stock value.
The following insider trend image provides a visual representation of the buying and selling activities by insiders over the past year:
For more detailed valuation, investors might refer to the GF Value of the stock to assess its potential fair value and make informed investment decisions.
This insider sale might be of interest to current and potential shareholders keeping an eye on insider behaviors as an indicator of the company's future prospects and valuation.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
